Halozyme Therapeutics (NASDAQ:HALO), a prominent player in the biotech industry, has shown a remarkable performance in the market over the past half-decade. The company has consistently outperformed the market, yielding an annualized return of 17.65% over the past 5 years, surpassing the market by 4.46%. This level of growth is a testament to the company’s […]